SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,375,000 | -30.3% | 232,466 | +0.4% | 0.00% | -33.3% |
| Q2 2023 | $4,844,000 | +27.4% | 231,443 | +28.6% | 0.01% | +20.0% |
| Q1 2023 | $3,802,000 | -17.0% | 180,000 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $4,581,000 | +5.3% | 180,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $4,349,000 | +24.9% | 180,000 | -0.5% | 0.01% | +25.0% |
| Q2 2022 | $3,482,000 | +10.7% | 180,991 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $3,145,000 | -20.6% | 180,991 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $3,962,000 | +14.5% | 180,991 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,459,000 | +11.3% | 180,991 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $3,108,000 | -23.2% | 180,991 | 0.0% | 0.00% | -50.0% |
| Q1 2021 | $4,047,000 | +1.1% | 180,991 | +0.6% | 0.01% | 0.0% |
| Q4 2020 | $4,003,000 | +50.7% | 180,000 | 0.0% | 0.01% | +50.0% |
| Q3 2020 | $2,657,000 | -0.4% | 180,000 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $2,668,000 | +35.1% | 180,000 | 0.0% | 0.01% | +25.0% |
| Q1 2020 | $1,975,000 | +25.0% | 180,000 | 0.0% | 0.00% | +100.0% |
| Q4 2019 | $1,580,000 | +17.5% | 180,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,345,000 | -73.2% | 180,000 | -66.7% | 0.00% | -33.3% |
| Q2 2019 | $5,028,000 | +432.1% | 540,000 | +200.0% | 0.00% | +50.0% |
| Q1 2019 | $945,000 | +18.0% | 180,000 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $801,000 | -44.9% | 180,000 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $1,454,000 | +15.0% | 180,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,264,000 | +11390.9% | 180,000 | +14900.0% | 0.00% | – |
| Q4 2017 | $11,000 | – | 1,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |